Trials / Completed
CompletedNCT02762812
Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis
International Multi-center Comparative Double-blind Randomized Clinical Trial to Evaluate Efficacy and Safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in Patients With Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Biocad · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
BCD-055-2 is international multi-center comparative double-blind randomized clinical trial to evaluate efficacy and safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in patients with ankylosing spondylitis. BCD-055 is biosimilar of infliximab (JSC "BIOCAD", Russia)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | BCD-055 | |
| BIOLOGICAL | Remicade® |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-05-01
- Completion
- 2017-07-01
- First posted
- 2016-05-05
- Last updated
- 2018-02-23
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT02762812. Inclusion in this directory is not an endorsement.